Bellevue Group AG
Bellevue Group AG reported 148 stocks worth $4.8B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are AMGN (6.5%), VRTX (6.0%) and ARGX (5.9%). Compared with Q1 2026, the fund opened new positions in AVLN, CGON and SPTX, added to AMGN, GILD and ORKA, trimmed VRTX, ARGX and RVMD and sold out of EWTX, INSP and PEN.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  AMGN Amgen Inc | $308M | 6.5% | 852K | +556K (+188%) | 8 of 8 | |
| 2 |  VRTX Vertex Pharmaceuticals I | $287M | 6.0% | 579K | −103K (−15%) | 8 of 8 | |
| 3 |  ARGX Argenx SE | $279M | 5.9% | 301K | −12K (−4%) | 8 of 8 | |
| 4 |  GILD Gilead Sciences Inc | $273M | 5.7% | 2.2M | +989K (+85%) | 8 of 8 | |
| 5 |  RVMD Revolution Medicines Inc | $196M | 4.1% | 1M | −496K (−32%) | 8 of 8 | |
| 6 |  ORKA Oruka Therapeutics Inc | $158M | 3.3% | 1.7M | +1.2M (+227%) | 2 of 8 | |
| 7 |  INSM Insmed Inc | $149M | 3.1% | 1.4M | +1.4M (+13787%) | 8 of 8 | |
| 8 |  SRRK Scholar Rock Hldg Corp | $135M | 2.8% | 2.4M | −1.1M (−32%) | 8 of 8 | |
| 9 | NUVALENT INC | $130M | 2.7% | 1.1M | No change | 3 of 8 | |
| 10 |  VRDN Viridian Therapeutics Inc | $124M | 2.6% | 6.7M | No change | 3 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 EWTX Edgewise Therapeutics Inc | $48.1M | 1.5M |
 INSP Inspire Med Sys Inc | $5.1M | 100K |
 PEN Penumbra Inc | $4M | 12K |
 RNA Atrium Therapeutics Inc | $3.5M | 263K |
MASIMO CORP | $1.6M | 8,753 |
🔒 Free account: see all 24.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Bellevue Group AG 13F FAQ
What does Bellevue Group AG own?
Bellevue Group AG reported 148 stocks worth $4.8B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are AMGN (6.5%), VRTX (6.0%) and ARGX (5.9%). The table above lists every position in the filing (the top 10 without an account).
What did Bellevue Group AG buy and sell in Q2 2026?
Compared with Q1 2026: 17 new positions, 39 added to, 65 trimmed and 24 sold out. New positions include AVLN, CGON and SPTX. It sold all of EWTX, INSP and PEN.
When will Bellevue Group AG file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Bellevue Group AG's portfolio worth?
The Q2 2026 filing reports $4.8B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.